Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid

Sponsor
Universitätsklinikum Hamburg-Eppendorf
Study ID
NCT02417103
Phase
PHASE3
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 77 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The aim of this study is to investigate the effect of the treatment with the GLP-1 Analogon Liraglutide on the lipid metabolism an inflammation in adipose tissue.

Key Dates

Start date
Dec 31, 2011
Status verified
Jun 2022
Primary completion
Sep 30, 2016
Completion
Dec 31, 2016

Study Design

Enrollment
2 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: GLP-1 (Liraglutide)
    Daily subcutaneous injection of Lirglutide over 9 weeks prior to bariatric surgery with a dosing of 0,6-1,8 mg
  • Placebo Comparator: Placebo Comparator
    Daily subcutaneous injection of PL1/PR1 Placebo over 9 weeks prior to bariatric surgery with a dosing of 0,6-1,8 mg

Primary Outcome Measure

weight reduction [ Time Frame: 4 years ]

Related Studies